Part 1 - Case Presentation

Erin Schenk, MD, PhD, and D. Ross Camidge, MD, PhD, medical oncologists at the University of Colorado Cancer Center, discuss the case of a 53-year-old woman with advanced stage IIIC non-small cell lung cancer (NSCLC). The patient is a current smoker, has an excellent performance status, but is symptomatic from disease burden. Drs Schenk and Camidge discuss treatment options for this patient in the context of current guidelines and data from clinical trials, such as KEYNOTE-189 and PACIFIC. In terms of treatment decision-making, the goals for this patient included the following: 1) to decrease disease burden; 2) to maximize disease control; and 3) to maximize long-term disease control.

Visit this link to continue to Part 2 - Case Discussion.

Disclosures:

Erin Schenk, MD, PhD
Consulting Fees: Guidepoint, Physicians’ Education Resource

D. Ross Camidge, MD, PhD
Consulting Fees: Amgen, Anchiarno, Apollomics, AstraZeneca, Bio-Thera, BMS, Daiichi-Sankyo, Eisai, Elevation, Eli Lilly, EMD Serono, GSK, Helssin, Janssen, Nuvalent, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda
Contracted Research: AbbVie, AstraZeneca, BMS, GSK, Hansoh, Inhibrx, Inivata, Karyopharm, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Symphogen, Takeda, Tolero